Novel Therapies for Metastatic Non-Small Cell Lung Cancer with MET Exon 14 Alterations: A Spotlight on Capmatinib.
Aaron C TanTracy J LohXue Lin KwangGek San TanKiat Hon LimDaniel Shao-Weng TanPublished in: Lung Cancer (Auckland, N.Z.) (2021)
MET exon 14 (METex14) alterations are now an established therapeutically tractable target in non-small cell lung cancer (NSCLC). Recently reported trials of several MET tyrosine kinase inhibitors (TKI) in this patient population have demonstrated promising efficacy data in both the treatment naïve and pre-treated settings and have led to regulatory approvals. This review will focus on practical diagnostic considerations for METex14 alterations, the trial evidence for capmatinib in this molecular subset including dosing and toxicity management, and the future therapeutic landscape of METex14 altered NSCLC.
Keyphrases
- tyrosine kinase
- small cell lung cancer
- advanced non small cell lung cancer
- epidermal growth factor receptor
- squamous cell carcinoma
- case report
- chronic myeloid leukemia
- study protocol
- randomized controlled trial
- brain metastases
- single cell
- phase ii
- current status
- machine learning
- replacement therapy
- open label
- deep learning
- data analysis
- double blind